Log In
Print
BCIQ
Print
Print this Print this
 

PeramiFlu, Rapiacta, Rapivab, peramivir

Also known as: BCX-1812, RWJ-270201

  Manage Alerts
Collapse Summary General Information
Company BioCryst Pharmaceuticals Inc.
DescriptionInjectable formulation of viral neuraminidase inhibitor
Molecular Target Neuraminidase
Mechanism of ActionNeuraminidase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInfluenza virus
Indication DetailsPrevent avian influenza (bird flu) infection; Treat acute influenza infection; Treat acute uncomplicated influenza in adults; Treat acute uncomplicated influenza in patients 18 or older who have been symptomatic for no more than two days; Treat and prevent influenza A and B strains; Treat and prevent swine influenza A (H1N1); Treat patients hospitalized for serious influenza infection; Treat seasonal influenza virus infection in children and infants
Regulatory Designation U.S. - Standard Review (Treat acute uncomplicated influenza in adults)
Partner CSL Ltd.; Green Cross Corp.; Shionogi & Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$45.7M

$33.7M

$12.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today